Rapid and sensitive method for measuring the plasma concentration of doxorubicin and its metabolites

Chemical and Pharmaceutical Bulletin

Volumn 60, Issue 3, 2012, Pages 391-396

  Sakai Kato, Kumiko ^a   Nanjo, Kunie ^a   Kawanishi, Toru ^a   Okuda, Haruhiro ^a  

^a NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

Author keywords

Doxorubicin; Metabolite; Pharmacokinetics

Indexed keywords

7 DEOXYDOXORUBICINOLONE; DAUNORUBICIN; DOXORUBICIN; DOXORUBICINOL; DOXORUBICINOLONE; DRUG METABOLITE; UNCLASSIFIED DRUG; VERAPAMIL;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; FEMALE; FLUORESCENCE; MOUSE; NONHUMAN; SENSITIVITY ANALYSIS; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY;

ANIMALS; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOXORUBICIN; FEMALE; MICE; MICE, INBRED BALB C;

EID: 84857887277     PISSN: 00092363     EISSN: 13475223     Source Type: Journal    
DOI: 10.1248/cpb.60.391     Document Type: Article

References (22)

1. Hortobágyi G. N., Drugs, 54 (Suppl. 4), 1-7 (1997).
2. Di Marco A., Gaetani M., Scarpinato B., Cancer Chemother. Rep., 53, 33-37 (1969).
3. O'Brien M. E., Wigler N., Inbar M., Rosso R., Grischke E., Santoro A., Catane R., Kieback D. G., Tomczak P., Ackland S. P., Orlandi F., Mellars L., Alland L., Tendler C., CAELYX Breast Cancer Study Group, Ann. Oncol., 15, 440-449 (2004).
4. Olson R. D., Mushlin P. S., Brenner D. E., Fleischer S., Cusack B. J., Chang B. K., Boucek R. J. Jr., Proc. Natl. Acad. Sci. U.S.A., 85, 3585-3589 (1988).
5. van Asperen J., van Tellingen O., Beijnen J. H., Drug Metab. Dispos., 28, 264-267 (2000).
6. Yokoyama M., Okano T., Sakurai Y., Fukushima S., Okamoto K., Kataoka K., J. Drug Target., 7, 171-186 (1999).
7. Nakanishi T., Fukushima S., Okamoto K., Suzuki M., Matsumura Y., Yokoyama M., Okano T., Sakurai Y., Kataoka K., J. Controlled Release, 74, 295-302 (2001).
8. Sakai-Kato K., Saito E., Ishikura K., Kawanishi T., J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 878, 1466-1470 (2010).
9. Swartz M. E., J. Liq. Chrom. Rel. Technol., 28, 1253-1263 (2005).
10. Nováková L., Vlcková H., Anal. Chim. Acta, 656, 8-35 (2009).
11. Sun N., Lu G., Lin M., Fan G., Wu Y., Talanta, 78, 506-512 (2009).
12. van Asperen J., van Tellingen O., Beijnen J. H., J. Chromatogr. B Biomed. Sci. Appl., 712, 129-143 (1998).
13. Zhou Q., Chowbay B., J. Pharm. Biomed. Anal., 30, 1063-1074 (2002).
14. Maudens K. E., Stove C. P., Lambert W. E., J. Sep. Sci., 31, 1042-1049 (2008).
15. Takanashi S., Bachur N. R., Drug Metab. Dispos., 4, 79-87 (1976).
16. Andersen A., Warren D. J., Slørdal L., Ther. Drug Monit., 15, 455-461 (1993).
17. Shinozawa S., Mimaki Y., Araki Y., Oda T., J. Chromatogr., 196, 463-469 (1980).
18. Rose L. M., Tillery K. F., el Dareer S. M., Hill D. L., J. Chromatogr., 425, 419-423 (1988).
19. Andersen A., Holte H., Slørdal L., Cancer Chemother. Pharmacol., 44, 422-426 (1999).
20. Guidance for Industry: Bioanalytical Method Validation. U.S. Department of Health and Human Services Food and Drug Administration (2001)
21. Lown J. W., Pharmacol. Ther., 60, 185-214 (1993).
22. van Asperen J., van Tellingen O., Tijssen F., Schinkel A. H., Beijnen J. H., Br. J. Cancer, 79, 108-113 (1999).